[go: up one dir, main page]

SG11201510011VA - Small molecule inhibitors of fibrosis - Google Patents

Small molecule inhibitors of fibrosis

Info

Publication number
SG11201510011VA
SG11201510011VA SG11201510011VA SG11201510011VA SG11201510011VA SG 11201510011V A SG11201510011V A SG 11201510011VA SG 11201510011V A SG11201510011V A SG 11201510011VA SG 11201510011V A SG11201510011V A SG 11201510011VA SG 11201510011V A SG11201510011V A SG 11201510011VA
Authority
SG
Singapore
Prior art keywords
fibrosis
small molecule
molecule inhibitors
inhibitors
small
Prior art date
Application number
SG11201510011VA
Inventor
Luke Lairson
Michael Bollong
Peter G Schultz
Arnab K Chatterjee
Baiyuan Yang
Puneet Kumar
Kaveri Urkalan
Original Assignee
California Inst Biomedical Res
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Inst Biomedical Res, Scripps Research Inst filed Critical California Inst Biomedical Res
Publication of SG11201510011VA publication Critical patent/SG11201510011VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Agronomy & Crop Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG11201510011VA 2013-06-07 2014-06-05 Small molecule inhibitors of fibrosis SG11201510011VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361832768P 2013-06-07 2013-06-07
PCT/US2014/041174 WO2014197738A1 (en) 2013-06-07 2014-06-05 Small molecule inhibitors of fibrosis

Publications (1)

Publication Number Publication Date
SG11201510011VA true SG11201510011VA (en) 2016-01-28

Family

ID=52008597

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201510011VA SG11201510011VA (en) 2013-06-07 2014-06-05 Small molecule inhibitors of fibrosis

Country Status (20)

Country Link
US (2) US9663499B2 (en)
EP (2) EP3003038B1 (en)
JP (1) JP6414831B2 (en)
KR (1) KR102240329B1 (en)
CN (1) CN105392364B (en)
AU (1) AU2014274830B2 (en)
BR (1) BR112015030203A2 (en)
CA (1) CA2913634C (en)
CL (1) CL2015003569A1 (en)
DK (1) DK3003038T3 (en)
EA (1) EA201592157A1 (en)
ES (2) ES2755125T3 (en)
HK (1) HK1221606A1 (en)
MX (1) MX2015016783A (en)
PE (1) PE20160523A1 (en)
PL (1) PL3003038T3 (en)
PT (1) PT3003038T (en)
SG (1) SG11201510011VA (en)
TN (1) TN2015000519A1 (en)
WO (1) WO2014197738A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107233337A (en) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 Pharmaceutical composition containing EPA and cardiovascular agents and use its method
WO2010147994A1 (en) 2009-06-15 2010-12-23 Amarin Pharma, Inc. Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
NZ727980A (en) 2010-11-29 2018-08-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
KR102240329B1 (en) 2013-06-07 2021-04-14 더 스크립스 리서치 인스티튜트 Small molecule inhibitors of fibrosis
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
WO2016094570A1 (en) 2014-12-10 2016-06-16 The California Institute For Biomedical Research Small molecule inhibitors of fibrosis
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment for modulating gut microbiota
EP3445385A4 (en) 2016-04-18 2019-11-20 The Trustees of Columbia University in the City of New York Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (nash)
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
CN106866459A (en) * 2017-03-30 2017-06-20 成都绿林科技有限公司 A kind of preparation method of antifungal drug intermediate
CN106986787A (en) * 2017-03-30 2017-07-28 成都绿林科技有限公司 A kind of synthetic method of posaconazole intermediate
JP2021517558A (en) * 2018-03-19 2021-07-26 シェオ ファーマスーティカルズ Methods and Compositions for Treating Idiopathic Pulmonary Fibrosis
ES2983568T3 (en) 2018-09-24 2024-10-23 Amarin Pharmaceuticals Ie Ltd Methods to reduce the risk of cardiovascular events in a subject
US12048686B2 (en) 2018-10-14 2024-07-30 The University Of Chicago Compositions and methods for activating NRF2-dependent gene expression
EP4058141A4 (en) 2019-11-12 2023-11-22 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
EP4132531A4 (en) * 2020-04-07 2024-04-17 Amarin Pharmaceuticals Ireland Limited METHOD FOR TREATING AND/OR PREVENTING VIRUS INFECTIONS AND/OR ILLNESSES DUE TO VIRUSES IN A DEMANDING PERSON
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4619931A (en) * 1983-02-28 1986-10-28 Janssen Pharmaceutica, N.V. [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles
US4791111A (en) * 1985-12-23 1988-12-13 Janssen Pharmaceutica, N.V. [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles having anti-microbial properties
IL103558A0 (en) * 1991-10-30 1993-03-15 Schering Corp Tri-substituted tetrahydrofuran antifungals
CN1041425C (en) 1993-11-19 1998-12-30 国际壳牌研究有限公司 Polyketone polymer compositions
US5521186A (en) 1994-10-27 1996-05-28 Janssen Pharmaceutica N.V. Apolipoprotein-β synthesis inhibitors
US5625064A (en) * 1995-04-19 1997-04-29 Schering Corporation Process for the preparation of triazolones
TW457240B (en) 1995-04-20 2001-10-01 Janssen Pharmaceutica Nv Novel triazolones as apolipoprotein-B synthesis inhibitors
EP0957101A1 (en) 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
DE60006541D1 (en) 1999-06-30 2003-12-18 Merck & Co Inc SRC-KINASE INHIBITING COMPOUNDS
EP1330448A2 (en) 2000-06-20 2003-07-30 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
EP1511490A4 (en) * 2002-05-31 2009-03-11 Transform Pharmaceuticals Inc Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
WO2009074300A2 (en) 2007-12-13 2009-06-18 Siena Biotech S.P.A. Hedgehog pathway antagonists and therapeutic applications thereof
US20100092479A1 (en) 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
JO3182B1 (en) 2009-07-29 2018-03-08 Regeneron Pharma Human antibiotics with high pH generation - 2
US20110183948A1 (en) 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
GB201015079D0 (en) * 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
WO2012047762A2 (en) 2010-10-08 2012-04-12 Amplyx Pharmaceuticals, Inc. Antifungal agents
SG191041A1 (en) 2010-12-07 2013-08-30 Amira Pharmaceuticals Inc Polycyclic lpa1 antagonist and uses thereof
US9346791B2 (en) * 2011-09-07 2016-05-24 The Johns Hopkins University Itraconazole analogs and use thereof
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
KR102240329B1 (en) 2013-06-07 2021-04-14 더 스크립스 리서치 인스티튜트 Small molecule inhibitors of fibrosis
US9790224B2 (en) 2013-06-07 2017-10-17 Rhizen Pharmaceuticals Sa Dual selective PI3 delta and gamma kinase inhibitors

Also Published As

Publication number Publication date
ES2755125T3 (en) 2020-04-21
EP3003038A1 (en) 2016-04-13
AU2014274830B2 (en) 2017-11-09
US9981956B2 (en) 2018-05-29
TN2015000519A1 (en) 2017-04-06
EP3626242B1 (en) 2024-08-07
US20170217943A1 (en) 2017-08-03
PT3003038T (en) 2019-11-19
KR20160029028A (en) 2016-03-14
AU2014274830A1 (en) 2015-11-26
KR102240329B1 (en) 2021-04-14
JP6414831B2 (en) 2018-10-31
EP3003038B1 (en) 2019-08-14
HK1221606A1 (en) 2017-06-09
CL2015003569A1 (en) 2016-11-11
JP2016521710A (en) 2016-07-25
PL3003038T3 (en) 2020-02-28
ES2991873T3 (en) 2024-12-05
BR112015030203A2 (en) 2017-07-25
CA2913634C (en) 2022-08-09
CN105392364A (en) 2016-03-09
EA201592157A1 (en) 2016-05-31
DK3003038T3 (en) 2019-11-11
US20160130258A1 (en) 2016-05-12
CN105392364B (en) 2018-09-14
WO2014197738A1 (en) 2014-12-11
EP3626242A1 (en) 2020-03-25
PE20160523A1 (en) 2016-05-25
MX2015016783A (en) 2016-07-18
CA2913634A1 (en) 2014-12-11
EP3003038A4 (en) 2016-11-16
US9663499B2 (en) 2017-05-30

Similar Documents

Publication Publication Date Title
SG11201510011VA (en) Small molecule inhibitors of fibrosis
IL242453B (en) Bipyrazole derivatives as jak inhibitors
IL241321A0 (en) Ido inhibitors
IL265496A (en) Bace1 inhibitors
ZA201506156B (en) Novel inhibitors
PL3021839T3 (en) Compositions for treatment of fibrosis
EP3250036A4 (en) Small molecule inhibitors of fibrosis
EP2994124A4 (en) INHIBITORS OF METALLO-ß-LACTAMASE-ENZYMES
IL240763B (en) Halogenopyrazoles as inhibitors of therombin
ZA201508010B (en) Inhibitors of metastasis
ZA201507100B (en) Synthesis of bace1 inhibitors
HUP1600222A2 (en) Small peptide inhibitors of �-amyloid toxicity
GB201312311D0 (en) Uses of enzyme inhibitors
GB201318284D0 (en) Construction of surfaces